Coeptis Therapeutics
Biopharmaceutical company developing allogeneic cell-therapy platforms for oncology, autoimmune, and infectious diseases, including a universal tag-adaptor CAR architecture, allogeneic NK-cell programs, and a cord blood-derived HSPC expansion/manufacturing platform. Operates a technology division that acquires and integrates software assets such as AI-driven marketing, robotic process automation (RPA), and data security/data-governance solutions to provide SaaS and managed services alongside its biotechnology programs. Headquartered in Wexford, PA.
Industries
Nr. of Employees
medium (51-250)
Coeptis Therapeutics
Wexford, Pennsylvania, United States, North America
Products
Modular tag-adaptor CAR platform
A modular CAR architecture where effector cells recognize a chemical tag on antibody adaptors to enable programmable multi-target cell therapy with tunable activity.
Clinical-stage allogeneic NK cell therapy
An in-licensed, unmodified NK cell therapy program in clinical development intended for use as an off-the-shelf cellular immunotherapy.
Scalable NK manufacturing platform from cord blood-derived HSPCs
Process for expanding pooled cord blood CD34+ cells via notch-mediated expansion and directed differentiation to produce large numbers of standardized NK cells suitable for commercial-scale distribution.
AI-driven marketing and automation platform
Software platform combining AI-driven campaign optimization, analytics, and RPA to automate marketing workflows and generate actionable insights for regulated industries.
Data security and governance software solutions
Software solutions for identifying, classifying, prioritizing, and protecting sensitive data across locations and platforms to support data privacy and compliance.
GEAR-NK
Modified natural killer cell-based therapeutics (NK cells) optimized to be co-administered with targeted antibodies.
Modular tag-adaptor CAR platform
A modular CAR architecture where effector cells recognize a chemical tag on antibody adaptors to enable programmable multi-target cell therapy with tunable activity.
Clinical-stage allogeneic NK cell therapy
An in-licensed, unmodified NK cell therapy program in clinical development intended for use as an off-the-shelf cellular immunotherapy.
Scalable NK manufacturing platform from cord blood-derived HSPCs
Process for expanding pooled cord blood CD34+ cells via notch-mediated expansion and directed differentiation to produce large numbers of standardized NK cells suitable for commercial-scale distribution.
AI-driven marketing and automation platform
Software platform combining AI-driven campaign optimization, analytics, and RPA to automate marketing workflows and generate actionable insights for regulated industries.
Data security and governance software solutions
Software solutions for identifying, classifying, prioritizing, and protecting sensitive data across locations and platforms to support data privacy and compliance.
GEAR-NK
Modified natural killer cell-based therapeutics (NK cells) optimized to be co-administered with targeted antibodies.
Services
Commercial deployment and managed services for an AI-powered marketing and automation platform combining campaign optimization, analytics, and RPA-driven workflow automation for regulated and enterprise customers.
Provision and integration of data discovery, classification, placement, and protection solutions to support privacy, compliance, and data governance programs for enterprise customers.
Commercial deployment and managed services for an AI-powered marketing and automation platform combining campaign optimization, analytics, and RPA-driven workflow automation for regulated and enterprise customers.
Provision and integration of data discovery, classification, placement, and protection solutions to support privacy, compliance, and data governance programs for enterprise customers.
Expertise Areas
- Allogeneic cell therapy development
- NK cell therapeutics
- Modular/tag-adaptor CAR engineering
- Cord blood HSPC expansion and directed differentiation
Key Technologies
- Tag-based universal CAR systems
- Allogeneic NK cell therapy methods
- Cord blood-derived CD34+ HSPC expansion
- Notch-mediated directed differentiation
News & Updates
Company participation at investor and industry conference.
Executed a binding letter of intent to acquire AI-powered marketing and RPA software assets to expand technology capabilities and operational efficiency for regulated industries.
Announced formation of a technology division and a binding LOI to acquire data security and risk-mitigation software assets to expand into data governance and enterprise security offerings.
Announcement of completion of a $10 million Series A preferred financing round to support technology and AI integration.
Announcement of initial customer contracts for the company's acquired AI-powered marketing platform.
Company announced a 1-for-20 reverse stock split to meet minimum listing price requirements.
Company participation at investor and industry conference.
Executed a binding letter of intent to acquire AI-powered marketing and RPA software assets to expand technology capabilities and operational efficiency for regulated industries.
Announced formation of a technology division and a binding LOI to acquire data security and risk-mitigation software assets to expand into data governance and enterprise security offerings.
Announcement of completion of a $10 million Series A preferred financing round to support technology and AI integration.
Announcement of initial customer contracts for the company's acquired AI-powered marketing platform.
Company announced a 1-for-20 reverse stock split to meet minimum listing price requirements.